ImmuPharma Statistics

Total Valuation

ImmuPharma has a market cap or net worth of GBP 8.08 million. The enterprise value is 7.68 million.

Market Cap	8.08M
Enterprise Value	7.68M

Important Dates

The last earnings date was Tuesday, August 5, 2025.

Earnings Date	Aug 5, 2025
Ex-Dividend Date	n/a

Share Statistics

ImmuPharma has 499.72 million shares outstanding. The number of shares has increased by 11.06% in one year.

Current Share Class	499.72M
Shares Outstanding	499.72M
Shares Change (YoY)	+11.06%
Shares Change (QoQ)	+15.22%
Owned by Insiders (%)	0.75%
Owned by Institutions (%)	84.20%
Float	459.81M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	24.00
P/TBV Ratio	24.36
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.95
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.05

Financial Position

The company has a current ratio of 1.21

Current Ratio	1.21
Quick Ratio	0.73
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-3.55

Financial Efficiency

Return on equity (ROE) is -259.88% and return on invested capital (ROIC) is -129.66%.

Return on Equity (ROE)	-259.88%
Return on Assets (ROA)	-69.57%
Return on Invested Capital (ROIC)	-129.66%
Return on Capital Employed (ROCE)	-932.85%
Revenue Per Employee	n/a
Profits Per Employee	-655,754
Employee Count	6
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	-199,359
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -5.96% in the last 52 weeks. The beta is 2.60, so ImmuPharma's price volatility has been higher than the market average.

Beta (5Y)	2.60
52-Week Price Change	-5.96%
50-Day Moving Average	2.14
200-Day Moving Average	2.60
Relative Strength Index (RSI)	34.40
Average Volume (20 Days)	2,189,452

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-3.14M
Pretax Income	-4.13M
Net Income	-3.93M
EBITDA	-3.14M
EBIT	-3.14M
Earnings Per Share (EPS)	-0.01

Full Income Statement

Balance Sheet

The company has 396,648 in cash and n/a in debt, giving a net cash position of 396,648 or 0.00 per share.

Cash & Cash Equivalents	396,648
Total Debt	n/a
Net Cash	396,648
Net Cash Per Share	0.00
Equity (Book Value)	336,699
Book Value Per Share	0.00
Working Capital	257,412

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.90 million and capital expenditures -1,652, giving a free cash flow of -1.90 million.

Operating Cash Flow	-1.90M
Capital Expenditures	-1,652
Free Cash Flow	-1.90M
FCF Per Share	-0.00

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

ImmuPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.06%
Shareholder Yield	n/a
Earnings Yield	-48.69%
FCF Yield	-23.50%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1